Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study

Sponsor
Karadeniz Technical University
Study ID
NCT04893031
Status
Completed

Conditions

  • COVID-19
  • Critical Care
  • Mortality
  • Tocilizumab

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    400mg or 800 mg IV tocilizumab treatment according to patient clinical severity

Study Details

Although its safety and efficacy in the COVID-19 patient population are still unclear, tocilizumab is one of treatment. Tocilizumab is a U.S. Food and Drug Administration approved IL-6 receptor antagonist widely used to treat CRS secondary to the chimeric antigen receptor T cell. In this study the investigators will evaluate the efficacy of Tocilizumab, an IL-6 antagonist administered in the early period in intensive care patients with COVID-19 pneumonia followed by hypoxic and systemic inflammation is predominant, but who do not support mechanical ventilation.

Key Dates

Start date
Mar 1, 2020
Status verified
May 2021
Primary completion
Mar 1, 2021
Completion
Apr 1, 2021

Study Design

Enrollment
213 participants (actual)

Arms

  • Arm: Tocilizumab treatment group
    Symptoms of hypoxia and systemic inflammation (SpO2 \<90% on room air with accompanying elevation of any two of the systemic inflammatory markers such as CRP, LDH and Ferritin) and / or acute bilateral infiltrations on chest radiography or rapid progression of existing infiltrations, but who did not need mechanical ventilation at admission and were given tocilizumab treatment.
  • Arm: Standard treatment group
    Patients who did not require mechanical ventilation in intensive care admission and did not receive tocilizumab treatment during any period of hospitalization.

Primary Outcome Measure

Rates of intensive care mortality in the groups [ Time Frame: 28 Day ]

Related Studies